Skip to main content
PMC home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2010 Jul;7(3):283–292. doi: 10.1016/j.nurt.2010.05.003

Immune dysfunction in autism: A pathway to treatment

Milo Careaga 1,2, Judy Van de Water 3, Paul Ashwood 1,2,✉
PMCID: PMC5084232  PMID: 20643381

Summary

Autism is a complex and clinically heterogeneous disorder with a spectrum of symptoms. Clinicians, schools, and service agencies worldwide have reported a dramatic increase in the number of children identified with autism. Despite expanding research, the etiology and underlying biological processes of autism remain poorly understood, and the relative contribution from genetic, epigenetic, and environmental factors remains unclear. Although autism affects primarily brain function (especially affect, social functioning, and cognition), it is unknown to what extent other organs and systems are disrupted. Published findings have identified widespread changes in the immune systems of children with autism, at both systemic and cellular levels. Brain specimens from autism subjects exhibit signs of active, ongoing inflammation, as well as alterations in gene pathways associated with immune signaling and immune function. Moreover, many genetic studies have indicated a link between autism and genes that are relevant to both the nervous system and the immune system. Alterations in these pathways can affect function in both systems. Together, these reports suggest that autism may in fact be a systemic disorder with connections to abnormal immune responses. Such immune system dysfunction may represent novel targets for treatment. A better understanding of the involvement of the immune response in autism, and of how early brain development is altered, may have important therapeutic implications.

Key words: Autism, immune system, autoimmunity, signaling pathways

References

  • 1.Money J, Bobrow NA, Clarke FC. Autism and autoimmune disease: a family study. J Autism Child Schizophr. 1971;1:146–160. doi: 10.1007/BF01537954. [DOI] [PubMed] [Google Scholar]
  • 2.Atladóttir HO, Pedersen MG, Thorsen P, et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics. 2009;124:687–694. doi: 10.1542/peds.2008-2445. [DOI] [PubMed] [Google Scholar]
  • 3.Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med. 2005;159:151–157. doi: 10.1001/archpedi.159.2.151. [DOI] [PubMed] [Google Scholar]
  • 4.Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33:197–207. doi: 10.1016/j.jaut.2009.09.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol. 1999;14:388–394. doi: 10.1177/088307389901400608. [DOI] [PubMed] [Google Scholar]
  • 6.Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics. 2003;112:e420–e420. doi: 10.1542/peds.112.5.e420. [DOI] [PubMed] [Google Scholar]
  • 7.Micali N, Chakrabarti S, Fombonne E. The broad autism phenotype: findings from an epidemiological survey. Autism. 2004;8:21–37. doi: 10.1177/1362361304040636. [DOI] [PubMed] [Google Scholar]
  • 8.Molloy CA, Morrow AL, Meinzen-Derr J, et al. Familial autoimmune thyroid disease as a risk factor for regression in children with autism spectrum disorder: a CPEA Study. J Autism Dev Disord. 2006;36:317–324. doi: 10.1007/s10803-005-0071-0. [DOI] [PubMed] [Google Scholar]
  • 9.Mouridsen SE, Rich B, Isager T, Nedergaard NJ. Autoimmune diseases in parents of children with infantile autism: a case-control study. Dev Med Child Neurol. 2007;49:429–432. doi: 10.1111/j.1469-8749.2007.00429.x. [DOI] [PubMed] [Google Scholar]
  • 10.Valicenti-McDermott MD, McVicar K, Cohen HJ, Wershil BK, Shinnar S. Gastrointestinal symptoms in children with an autism spectrum disorder and language regression. Pediatr Neurol. 2008;39:392–398. doi: 10.1016/j.pediatrneurol.2008.07.019. [DOI] [PubMed] [Google Scholar]
  • 11.Tincani A, Rebaioli CB, Frassi M, et al. Pregnancy Study Group of Italian Society of Rheumatology. Pregnancy and autoimmunity: maternal treatment and maternal disease influence on pregnancy outcome. Autoimmun Rev. 2005;4:423–428. doi: 10.1016/j.autrev.2005.03.001. [DOI] [PubMed] [Google Scholar]
  • 12.Croen LA, Braunschweig D, Haapanen L, et al. Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study. Biol Psychiatry. 2008;64:583–588. doi: 10.1016/j.biopsych.2008.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Warren RP, Cole P, Odell JD, et al. Detection of maternal antibodies in infantile autism. J Am Acad Child Adolesc Psychiatry. 1990;29:873–877. doi: 10.1097/00004583-199011000-00005. [DOI] [PubMed] [Google Scholar]
  • 14.Dalton P, Deacon R, Blamire A, et al. Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol. 2003;53:533–537. doi: 10.1002/ana.10557. [DOI] [PubMed] [Google Scholar]
  • 15.Zimmerman AW, Connors SL, Matteson KJ, et al. Maternal antibrain antibodies in autism. Brain Behav Immun. 2007;21:351–357. doi: 10.1016/j.bbi.2006.08.005. [DOI] [PubMed] [Google Scholar]
  • 16.Braunschweig D, Ashwood P, Krakowiak P, et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology. 2008;29:226–231. doi: 10.1016/j.neuro.2007.10.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Singer HS, Morris CM, Gause CD, Gillin PK, Crawford S, Zimmerman AW. Antibodies against fetal brain in sera of mothers with autistic children. J Neuroimmunol. 2008;194:165–172. doi: 10.1016/j.jneuroim.2007.11.004. [DOI] [PubMed] [Google Scholar]
  • 18.Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun. 2008;22:806–816. doi: 10.1016/j.bbi.2007.12.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Singer HS, Morris C, Gause C, Pollard M, Zimmerman AW, Pletnikov M. Prenatal exposure to antibodies from mothers of children with autism produces neurobehavioral alterations: a pregnant dam mouse model. J Neuroimmunol. 2009;211:39–48. doi: 10.1016/j.jneuroim.2009.03.011. [DOI] [PubMed] [Google Scholar]
  • 20.Silva SC, Correia C, Fesel C, et al. Autoantibody repertoires to brain tissue in autism nuclear families. J Neuroimmunol. 2004;152:176–182. doi: 10.1016/j.jneuroim.2004.03.015. [DOI] [PubMed] [Google Scholar]
  • 21.McAllister DL, Kaplan BJ, Edworthy SM, et al. The influence of systemic lupus erythematosus on fetal development: cognitive, behavioral, and health trends. J Int Neuropsychol Soc. 1997;3:370–376. [PubMed] [Google Scholar]
  • 22.Neri F, Chimini L, Bonomi F, et al. Neuropsychological development of children born to patients with systemic lupus erythematosus. Lupus. 2004;13:805–811. doi: 10.1191/0961203304lu2018oa. [DOI] [PubMed] [Google Scholar]
  • 23.Tincani A, Danieli E, Nuzzo M, et al. Pregancy Study Group of Italian Society of Rheumatology. Impact of in utero environment on the offspring of lupus patients. Lupus. 2006;15:801–807. doi: 10.1177/0961203306071005. [DOI] [PubMed] [Google Scholar]
  • 24.Lee LA. The clinical spectrum of neonatal lupus. Arch Dermatol Res. 2009;301:107–110. doi: 10.1007/s00403-008-0896-4. [DOI] [PubMed] [Google Scholar]
  • 25.Lee JY, Huerta PT, Zhang J, et al. Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med. 2009;15:91–96. doi: 10.1038/nm.1892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Klauck SM, Poustka A. Animal models of autism. Drug Discov Today Dis Models. 2006;3:313–318. [Google Scholar]
  • 27.Enstrom AM, Van de Water JA, Ashwood P. Autoimmunity in autism. Curr Opin Investig Drugs. 2009;10:463–473. [PMC free article] [PubMed] [Google Scholar]
  • 28.Fernando MM, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 2008;4:e1000024–e1000024. doi: 10.1371/journal.pgen.1000024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Stubbs EG, Magenis RE. HLA and autism. J Autism Dev Disord. 1980;10:15–19. doi: 10.1007/BF02408429. [DOI] [PubMed] [Google Scholar]
  • 30.Stubbs EG, Ritvo ER, Mason-Brothers A. Autism and shared parental HLA antigens. J Am Acad Child Psychiatry. 1985;24:182–185. doi: 10.1016/s0002-7138(09)60445-3. [DOI] [PubMed] [Google Scholar]
  • 31.Spence MA, Ritvo ER, Marazita ML, Funderburk SJ, Sparkes RS, Freeman BJ. Gene mapping studies with the syndrome of autism. Behav Genet. 1985;15:1–13. doi: 10.1007/BF01071928. [DOI] [PubMed] [Google Scholar]
  • 32.Warren RP, Singh VK, Cole P, et al. Possible association of the extended MHC haplotype B44-SC30-DR4 with autism. Immunogenetics. 1992;36:203–207. doi: 10.1007/BF00215048. [DOI] [PubMed] [Google Scholar]
  • 33.Daniels WW, Warren RP, Odell JD, et al. Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism. Neuropsychobiology. 1995;32:120–123. doi: 10.1159/000119223. [DOI] [PubMed] [Google Scholar]
  • 34.Warren RP, Singh VK, Averett RE, et al. Immunogenetic studies in autism and related disorders. Mol Chem Neuropathol. 1996;28:77–81. doi: 10.1007/BF02815207. [DOI] [PubMed] [Google Scholar]
  • 35.Rogers T, Kalaydjieva L, Hallmayer J, et al. Exclusion of linkage to the HLA region in ninety multiplex sibships with autism. J Autism Dev Disord. 1999;29:195–201. doi: 10.1023/a:1023075904742. [DOI] [PubMed] [Google Scholar]
  • 36.Tones AR, Maciulis A, Stubbs EG, Cutler A, Odell D. The transmission disequilibrium test suggests that HLA-DR4 and DR13 are linked to autism spectrum disorder. Hum Immunol. 2002;63:311–316. doi: 10.1016/s0198-8859(02)00374-9. [DOI] [PubMed] [Google Scholar]
  • 37.Lee LC, Zachary AA, Leffell MS, et al. HLA-DR4 in families with autism. Pediatr Neurol. 2006;35:303–307. doi: 10.1016/j.pediatrneurol.2006.06.006. [DOI] [PubMed] [Google Scholar]
  • 38.Guerini FR, Bolognesi E, Manca S, et al. Family-based transmission analysis of HLA genetic markers in Sardinian children with autistic spectrum disorders. Hum Immunol. 2009;70:184–190. doi: 10.1016/j.humimm.2008.12.009. [DOI] [PubMed] [Google Scholar]
  • 39.Johnson WG, Buyske S, Mars AE, et al. HLA-DR4 as a risk allele for autism acting in mothers of probands possibly during pregnancy. Arch Pediatr Adolesc Med. 2009;163:542–546. doi: 10.1001/archpediatrics.2009.74. [DOI] [PubMed] [Google Scholar]
  • 40.Wan-en RP, Burger RA, Odell D, Tones AR, Warren WL. Decreased plasma concentrations of the C4B complement protein in autism. Arch Pediatr Adolesc Med. 1994;148:180–183. doi: 10.1001/archpedi.1994.02170020066011. [DOI] [PubMed] [Google Scholar]
  • 41.Wan-en RP, Yonk J, Burger RW, Odell D, Wan-en WL. DR-positive T cells in autism: association with decreased plasma levels of the complement C4B protein. Neuropsychobiology. 1995;31:53–57. doi: 10.1159/000119172. [DOI] [PubMed] [Google Scholar]
  • 42.Odell D, Maciulis A, Cutler A, et al. Confirmation of the association of the C4B null allele in autism. Hum Immunol. 2005;66:140–145. doi: 10.1016/j.humimm.2004.11.002. [DOI] [PubMed] [Google Scholar]
  • 43.Grigorenko EL, Han SS, Yrigollen CM, et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics. 2008;122:e438–e445. doi: 10.1542/peds.2007-3604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Correll PH, Morrison AC, Lutz MA. Receptor tyrosine kinases and the regulation of macrophage activation. J Leukoc Biol. 2004;75:731–737. doi: 10.1189/jlb.0703347. [DOI] [PubMed] [Google Scholar]
  • 45.Lintas C, Sacco R, Garbett K, et al. Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression. Mol Psychiatry. 2009;14:705–718. doi: 10.1038/mp.2008.21. [DOI] [PubMed] [Google Scholar]
  • 46.Herman GE, Butter E, Emile B, Pastore M, Prior TW, Sommer A. Increasing knowledge of PTEN germline mutations: two additional patients with autism and macrocephaly. Am J Med Genet A. 2007;143:589–593. doi: 10.1002/ajmg.a.31619. [DOI] [PubMed] [Google Scholar]
  • 47.Serajee FJ, Zhong H, Mahbubul Huq AH. Association of Reelin gene polymorphisms with autism. Genomics. 2006;87:75–83. doi: 10.1016/j.ygeno.2005.09.008. [DOI] [PubMed] [Google Scholar]
  • 48.Skaar DA, Shao Y, Haines JL, et al. Analysis of the RELN gene as a genetic risk factor for autism. Mol Psychiatry. 2005;10:563–571. doi: 10.1038/sj.mp.4001614. [DOI] [PubMed] [Google Scholar]
  • 49.Zhang H, Liu X, Zhang C, et al. Reelin gene alleles and susceptibility to autism spectrum disorders. Mol Psychiatry. 2002;7:1012–1017. doi: 10.1038/sj.mp.4001124. [DOI] [PubMed] [Google Scholar]
  • 50.Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism [Erratum in: Ann Neurol 2005;57:304] Ann Neurol. 2005;57:67–81. doi: 10.1002/ana.20315. [DOI] [PubMed] [Google Scholar]
  • 51.Ashwood P, Anthony A, Torrente F, Wakefield AJ. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J Clin Immunol. 2004;24:664–673. doi: 10.1007/s10875-004-6241-6. [DOI] [PubMed] [Google Scholar]
  • 52.Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol. 2006;173:126–134. doi: 10.1016/j.jneuroim.2005.12.007. [DOI] [PubMed] [Google Scholar]
  • 53.Singh VK, Wan-en RP, Odell JD, Cole P. Changes of soluble interleukin-2, interleukin-2 receptor, T8 antigen, and interleukin-1 in the serum of autistic children. Clin Immunol Immunopathol. 1991;61:448–455. doi: 10.1016/s0090-1229(05)80015-7. [DOI] [PubMed] [Google Scholar]
  • 54.Singh VK. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol. 1996;66:143–145. doi: 10.1016/0165-5728(96)00014-8. [DOI] [PubMed] [Google Scholar]
  • 55.Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol. 2001;120:170–179. doi: 10.1016/s0165-5728(01)00421-0. [DOI] [PubMed] [Google Scholar]
  • 56.Ashwood P, Enstrom A, Krakowiak P, et al. Decreased transforming growth factor betal in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol. 2008;204:149–153. doi: 10.1016/j.jneuroim.2008.07.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46:76–84. doi: 10.1159/000065416. [DOI] [PubMed] [Google Scholar]
  • 58.Ashwood P, Anthony A, Pellicer AA, Torrente F, Walker-Smith JA, Wakefield AJ. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol. 2003;23:504–517. doi: 10.1023/b:joci.0000010427.05143.bb. [DOI] [PubMed] [Google Scholar]
  • 59.Horvath K, Perman JA. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep. 2002;4:251–258. doi: 10.1007/s11894-002-0071-6. [DOI] [PubMed] [Google Scholar]
  • 60.Genuis SJ, Bouchard TP. Celiac disease presenting as autism. J Child Neurol. 2010;25:114–119. doi: 10.1177/0883073809336127. [DOI] [PubMed] [Google Scholar]
  • 61.Wills S, Cabanlit M, Bennett J, Ashwood P, Amaral D, Van de Water J. Autoantibodies in autism spectrum disorders (ASD) Ann N Y Acad Sci. 2007;1107:79–91. doi: 10.1196/annals.1381.009. [DOI] [PubMed] [Google Scholar]
  • 62.Todd RD, Ciaranello RD. Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc Natl Acad Sci U S A. 1985;82:612–616. doi: 10.1073/pnas.82.2.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Singh VK, Wan-en RP, Odell JD, Wan-en WL, Cole P. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immun. 1993;7:97–103. doi: 10.1006/brbi.1993.1010. [DOI] [PubMed] [Google Scholar]
  • 64.Singh VK, Warren R, Averett R, Ghaziuddin M. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr Neurol. 1997;17:88–90. doi: 10.1016/s0887-8994(97)00045-3. [DOI] [PubMed] [Google Scholar]
  • 65.Singh VK, Lin SX, Yang VC. Serological association of measles virus and human herpesvirus-6 with brain autoantibodies in autism. Clin Immunol Immunopathol. 1998;89:105–108. doi: 10.1006/clin.1998.4588. [DOI] [PubMed] [Google Scholar]
  • 66.Evers M, Cunningham-Rundles C, Hollander E. Heat shock protein 90 antibodies in autism. Mol Psychiatry. 2002;7(Suppl 2):S26–S28. doi: 10.1038/sj.mp.4001171. [DOI] [PubMed] [Google Scholar]
  • 67.Vojdani A, O’Bryan T, Green JA, et al. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nute Neurosci. 2004;7:151–161. doi: 10.1080/10284150400004155. [DOI] [PubMed] [Google Scholar]
  • 68.Singh VK, Rivas WH. Prevalence of serum antibodies to caudate nucleus in autistic children. Neurosci Lett. 2004;355:53–56. doi: 10.1016/j.neulet.2003.10.026. [DOI] [PubMed] [Google Scholar]
  • 69.Singh VK, Rivas WH. Detection of antinuclear and antilaminin antibodies in autistic children who received thimerosal-containing vaccines. J Biomed Sci. 2004;11:607–610. doi: 10.1007/BF02256125. [DOI] [PubMed] [Google Scholar]
  • 70.Connolly AM, Chez M, Streif EM, et al. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry. 2006;59:354–363. doi: 10.1016/j.biopsych.2005.07.004. [DOI] [PubMed] [Google Scholar]
  • 71.Singer HS, Morris CM, Williams PN, Yoon DY, Hong JJ, Zimmerman AW. Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol. 2006;178:149–155. doi: 10.1016/j.jneuroim.2006.05.025. [DOI] [PubMed] [Google Scholar]
  • 72.Libbey JE, Coon HH, Kirkman NJ, et al. Are there enhanced MBP autoantibodies in autism? J Autism Dev Disord. 2008;38:324–332. doi: 10.1007/s10803-007-0400-6. [DOI] [PubMed] [Google Scholar]
  • 73.Kirkman NJ, Libbey JE, Sweeten TL, et al. How relevant are GFAP autoantibodies in autism and Tourette Syndrome? J Autism Dev Disord. 2008;38:333–341. doi: 10.1007/s10803-007-0398-9. [DOI] [PubMed] [Google Scholar]
  • 74.Wills S, Cabanlit M, Bennett J, Ashwood P, Amaral DG, Van de Water J. Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders. Brain Behav Immun. 2009;23:64–74. doi: 10.1016/j.bbi.2008.07.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Torrente F, Ashwood P, Day R, et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry. 2002;7:375–382. doi: 10.1038/sj.mp.4001077. [DOI] [PubMed] [Google Scholar]
  • 76.Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484. doi: 10.1016/j.cell.2006.01.016. [DOI] [PubMed] [Google Scholar]
  • 77.Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord. 2007;37:738–747. doi: 10.1007/s10803-006-0205-z. [DOI] [PubMed] [Google Scholar]
  • 78.Wiznitzer M. Autism and tuberous sclerosis. J Child Neurol. 2004;19:675–679. doi: 10.1177/08830738040190090701. [DOI] [PubMed] [Google Scholar]
  • 79.Williams PG, Hersh JH. Brief report: the association of neurofibromatosis type 1 and autism. J Autism Dev Disord. 1998;28:567–571. doi: 10.1023/a:1026012414193. [DOI] [PubMed] [Google Scholar]
  • 80.Cuscó I, Medrano A, Gener B, et al. Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorder. Hum Mol Genet. 2009;18:1795–1804. doi: 10.1093/hmg/ddp092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Stubbs EG. Autistic children exhibit undetectable hemagglutination-inhibition antibody titers despite previous rubella vaccination. J Autism Child Schizophr. 1976;6:269–274. doi: 10.1007/BF01543467. [DOI] [PubMed] [Google Scholar]
  • 82.Warren RP, Margaretten NC, Pace NC, Foster A. Immune abnormalities in patients with autism. J Autism Dev Disord. 1986;16:189–197. doi: 10.1007/BF01531729. [DOI] [PubMed] [Google Scholar]
  • 83.Murch SH, Fertleman CR, Rodrigues C, et al. Autoimmune enteropathy with distinct mucosal features in T-cell activation deficiency: the contribution of T cells to the mucosal lesion. J Pediatr Gastroenterol Nute. 1999;28:393–399. doi: 10.1097/00005176-199904000-00009. [DOI] [PubMed] [Google Scholar]
  • 84.Mondino A, Mueller DL. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol. 2007;19:162–172. doi: 10.1016/j.smim.2007.02.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ. 2002;9:99–100. doi: 10.1038/sj.cdd.4400978. [DOI] [PubMed] [Google Scholar]
  • 86.Engstrom HA, Ohlson S, Stubbs EG, et al. Decreased expression of CD95 (FAS/APO-1) on CD4+ T-lymphocytes from participants with autism. J Dev Phys Disabil. 2003;15:155–163. [Google Scholar]
  • 87.Fatemi SH, Stary JM, Halt AR, Realmuto GR. Dysregulation of reelin and Bcl-2 proteins in autistic cerebellum. J Autism Dev Disord. 2001;31:529–535. doi: 10.1023/a:1013234708757. [DOI] [PubMed] [Google Scholar]
  • 88.Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A. 2008;105:7797–7802. doi: 10.1073/pnas.0800928105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Wu T, Mohan C. The AKT axis as a therapeutic target in autoimmune diseases. Endocr Metab Immune Disord Drug Targets. 2009;9:145–150. doi: 10.2174/187153009788452417. [DOI] [PubMed] [Google Scholar]
  • 90.Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology. 2005;51:77–85. doi: 10.1159/000084164. [DOI] [PubMed] [Google Scholar]
  • 91.Weichhart T, Costantino G, Poglitsch M, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity. 2008;29:565–577. doi: 10.1016/j.immuni.2008.08.012. [DOI] [PubMed] [Google Scholar]
  • 92.Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol. 2007;17:434–447. doi: 10.1111/j.1750-3639.2007.00102.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Volkmar FR, Pauls D. Autism [Erratum in: Lancet 2004;363: 250] Lancet. 2003;362:1133–1141. doi: 10.1016/S0140-6736(03)14471-6. [DOI] [PubMed] [Google Scholar]
  • 94.Kemper TL, Bauman ML. Neuropathology of infantile autism. Mol Psychiatry. 2002;7(Suppl 2):S12–S13. doi: 10.1038/sj.mp.4001165. [DOI] [PubMed] [Google Scholar]
  • 95.Courchesne E, Pierce K. Brain overgrowth in autism during a critical time in development: implications for frontal pyramidal neuron and intemeuron development and connectivity. Int J Dev Neurosci. 2005;23:153–170. doi: 10.1016/j.ijdevneu.2005.01.003. [DOI] [PubMed] [Google Scholar]
  • 96.Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil. 2006;27:254–289. doi: 10.1016/j.ridd.2005.03.003. [DOI] [PubMed] [Google Scholar]
  • 97.Anderson GM, Home WC, Chatterjee D, Cohen DJ. The hyperserotonemia of autism. Ann N Y Acad Sci. 1990;600:331–340. doi: 10.1111/j.1749-6632.1990.tb16893.x. [DOI] [PubMed] [Google Scholar]
  • 98.Rolf LH, Haarmann FY, Grotemeyer KH, Kehrer H. Serotonin and amino acid content in platelets of autistic children. Acta Psychiatr Scand. 1993;87:312–316. doi: 10.1111/j.1600-0447.1993.tb03378.x. [DOI] [PubMed] [Google Scholar]
  • 99.Singh VK, Singh EA, Warren RP. Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol Psychiatry. 1997;41:753–755. doi: 10.1016/S0006-3223(96)00522-7. [DOI] [PubMed] [Google Scholar]
  • 100.McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Rice LH. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 1996;53:993–1000. doi: 10.1001/archpsyc.1996.01830110029004. [DOI] [PubMed] [Google Scholar]
  • 101.Dunn AJ, Wang J, Ando T. Effects of cytokines on cerebral neurotransmission: comparison with the effects of stress. Adv Exp Med Biol. 1999;461:117–127. doi: 10.1007/978-0-585-37970-8_8. [DOI] [PubMed] [Google Scholar]
  • 102.Wirleitner B, Neurauter G, Schröcksnadel K, Frick B, Fuchs D. Interferon-γ-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem. 2003;10:1581–1591. doi: 10.2174/0929867033457179. [DOI] [PubMed] [Google Scholar]
  • 103.Bjurstöm H, Wang J, Ericsson I, et al. GABA, a natural immunomodulator of T lymphocytes. J Neuroimmunol. 2008;205:44–104. doi: 10.1016/j.jneuroim.2008.08.017. [DOI] [PubMed] [Google Scholar]
  • 104.Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol. 2008;8:460–471. doi: 10.1016/j.coph.2008.05.001. [DOI] [PubMed] [Google Scholar]
  • 105.Pacheco R, Gallart T, Lluis C, Franco R. Role of glutamate on T-cell mediated immunity. J Neuroimmunol. 2007;185:9–19. doi: 10.1016/j.jneuroim.2007.01.003. [DOI] [PubMed] [Google Scholar]
  • 106.Pacheco R, Ciruela F, Casadó V, et al. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J Biol Chem. 2004;279:33352–33358. doi: 10.1074/jbc.M401761200. [DOI] [PubMed] [Google Scholar]
  • 107.Sarchielli P, Di Filippo M, Candeliere A, et al. Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. J Neuroimmunol. 2007;188:146–158. doi: 10.1016/j.jneuroim.2007.05.021. [DOI] [PubMed] [Google Scholar]
  • 108.Pacheco R, Oliva H, Martinez-Navio JM, et al. Glutamate released by dendritic cells as a novel modulator of T cell activation. J Immunol. 2006;177:6695–6704. doi: 10.4049/jimmunol.177.10.6695. [DOI] [PubMed] [Google Scholar]
  • 109.Alam S, Laughton DL, Walding A, Wolstenholme AJ. Human peripheral blood mononuclear cells express GABAA receptor subunits. Mol Immunol. 2006;43:1432–1442. doi: 10.1016/j.molimm.2005.07.025. [DOI] [PubMed] [Google Scholar]
  • 110.Lubick K, Radke M, Jutila M. Securinine, a GABAA receptor antagonist, enhances macrophage clearance of phase II C. burnetii: comparison with TLR agonists [Erratum in: J Leukoc Biol 2008;83:1068] J Leukoc Biol. 2007;82:1062–1069. doi: 10.1189/jlb.0407255. [DOI] [PubMed] [Google Scholar]
  • 111.Levite M, Ganor Y. Autoantibodies to glutamate receptors can damage the brain in epilepsy, systemic lupus erythematosus and encephalitis. Expert Rev Neurother. 2008;8:1141–1160. doi: 10.1586/14737175.8.7.1141. [DOI] [PubMed] [Google Scholar]
  • 112.Volkmar FR, Nelson DS. Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry. 1990;29:127–129. doi: 10.1097/00004583-199001000-00020. [DOI] [PubMed] [Google Scholar]
  • 113.Raju R, Rakocevic G, Chen Z, et al. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain. 2006;129:3270–3276. doi: 10.1093/brain/awl245. [DOI] [PubMed] [Google Scholar]
  • 114.Ghaziuddin M, Butler E. Clumsiness in autism and Asperger syndrome: a further report. J Intellect Disabil Res. 1998;42:43–48. doi: 10.1046/j.1365-2788.1998.00065.x. [DOI] [PubMed] [Google Scholar]
  • 115.Levy SE, Mandell DS, Merhar S, Ittenbach RF, Pinto-Martin JA. Use of complementary and alternative medicine among children recently diagnosed with autistic spectrum disorder. J Dev Behav Pediatr. 2003;24:418–423. doi: 10.1097/00004703-200312000-00003. [DOI] [PubMed] [Google Scholar]
  • 116.Hanson E, Kalish L, Bunce E, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord. 2007;37:628–636. doi: 10.1007/s10803-006-0192-0. [DOI] [PubMed] [Google Scholar]
  • 117.Harrington JW, Rosen L, Garnecho A, Patrick PA. Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice. J Dev Behav Pediatr. 2006;27:S156–S161. doi: 10.1097/00004703-200604002-00014. [DOI] [PubMed] [Google Scholar]
  • 118.Wong HH, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord. 2006;36:901–909. doi: 10.1007/s10803-006-0131-0. [DOI] [PubMed] [Google Scholar]
  • 119.Golnik A, Ireland M. complementary alternative medicine for children with autism: a physician survey. J Autism Dev Disord. 2009;39:996–1005. doi: 10.1007/s10803-009-0714-7. [DOI] [PubMed] [Google Scholar]
  • 120.Geier MR, Geier DA. The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses. 2005;64:946–954. doi: 10.1016/j.mehy.2004.11.018. [DOI] [PubMed] [Google Scholar]
  • 121.Buitelaar JK, van Engeland H, van Ree JM, de Wied D. Behavioral effects of Org 2766, a synthetic analog of the adrenocorticotrophic hormone (4–9), in 14 outpatient autistic children. J Autism Dev Disord. 1990;20:467–478. doi: 10.1007/BF02216053. [DOI] [PubMed] [Google Scholar]
  • 122.Bradstreet JJ, Smith S, Granpeesheh D, El-Dahr JM, Rossignol D. Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders. Med Hypotheses. 2007;68:979–987. doi: 10.1016/j.mehy.2006.10.015. [DOI] [PubMed] [Google Scholar]
  • 123.Matarazzo EB. Treatment of late onset autism as a consequence of probable autoimmune processes related to chronic bacterial infection. World J Biol Psychiatry. 2002;3:162–166. doi: 10.3109/15622970209150618. [DOI] [PubMed] [Google Scholar]
  • 124.Shenoy S, Arnold S, Chatila T. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr. 2000;136:682–687. doi: 10.1067/mpd.2000.105355. [DOI] [PubMed] [Google Scholar]
  • 125.Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med. 1997;126:721–730. doi: 10.7326/0003-4819-126-9-199705010-00008. [DOI] [PubMed] [Google Scholar]
  • 126.Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol. 1998;13:79–82. doi: 10.1177/088307389801300207. [DOI] [PubMed] [Google Scholar]
  • 127.Gupta S. Treatment of children with autism with intravenous immunoglobulin. J Child Neurol. 1999;14:203–205. [PubMed] [Google Scholar]
  • 128.Sandler RH, Finegold SM, Bolte ER, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol. 2000;15:429–435. doi: 10.1177/088307380001500701. [DOI] [PubMed] [Google Scholar]
  • 129.Cannell JJ. Autism and vitamin D. Med Hypotheses. 2008;70:750–759. doi: 10.1016/j.mehy.2007.08.016. [DOI] [PubMed] [Google Scholar]
  • 130.Sandler A. Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev. 2005;11:164–170. doi: 10.1002/mrdd.20065. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES